TY - JOUR
T1 - Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients
AU - van der Feen, Cathelijne
AU - van der Doef, Hubert P J
AU - van der Ent, Cornelis K
AU - Houwen, Roderick H J
N1 - Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
PY - 2016/11
Y1 - 2016/11
N2 - BACKGROUND: Ursodeoxycholic acid (UDCA) might prevent progression of cystic fibrosis liver disease, but objective parameters for its effect are lacking.METHODS: We used liver stiffness measurements to evaluate the effect of Ursodeoxycholic acid.RESULTS: Paired measurements of liver stiffness were done in 73 patients without UDCA and in 32 patients with UDCA. In the latter group, 6 patients had cirrhosis; in 15 patients, UDCA was started based on Colombo criteria, and in 11 patients for other reasons. In patients without UDCA, liver stiffness increased: 0.19 (-0.03 to 0.59)kPa/year. Liver stiffness also increased in patients with cirrhosis: 4.6 (0.67-12.4)kPa/year. In patients who had UDCA based on Colombo criteria, a decrease of liver stiffness was observed: 0.70 (-1.6 to 0.55)kPa/year (P=0.01). In patients on UDCA for other reasons, liver stiffness increased: 0.23 (-0.20 to 0.51)kPa/year.CONCLUSION: UDCA reduced liver stiffness in patients with well-defined, mild liver disease.
AB - BACKGROUND: Ursodeoxycholic acid (UDCA) might prevent progression of cystic fibrosis liver disease, but objective parameters for its effect are lacking.METHODS: We used liver stiffness measurements to evaluate the effect of Ursodeoxycholic acid.RESULTS: Paired measurements of liver stiffness were done in 73 patients without UDCA and in 32 patients with UDCA. In the latter group, 6 patients had cirrhosis; in 15 patients, UDCA was started based on Colombo criteria, and in 11 patients for other reasons. In patients without UDCA, liver stiffness increased: 0.19 (-0.03 to 0.59)kPa/year. Liver stiffness also increased in patients with cirrhosis: 4.6 (0.67-12.4)kPa/year. In patients who had UDCA based on Colombo criteria, a decrease of liver stiffness was observed: 0.70 (-1.6 to 0.55)kPa/year (P=0.01). In patients on UDCA for other reasons, liver stiffness increased: 0.23 (-0.20 to 0.51)kPa/year.CONCLUSION: UDCA reduced liver stiffness in patients with well-defined, mild liver disease.
KW - Cystic fibrosis liver disease
KW - Ursodeoxycholic acid
KW - Liver stiffness measurement
KW - Fibroscan
U2 - 10.1016/j.jcf.2016.07.009
DO - 10.1016/j.jcf.2016.07.009
M3 - Article
C2 - 27481229
SN - 1569-1993
VL - 15
SP - 834
EP - 838
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
IS - 6
ER -